Ross' Story In 2015, Ross was diagnosed with stage 2A cutaneous melanoma and underwent wide local excision (WLE) and sentinel lymph node biopsy (SLNB) treatment.

Ross is sharing his story to remind others to stay vigilant and to offer hope to those facing melanoma:

“To never give up… I have seen miraculous things happen.”

You can read his full story HERE: bit.ly/PatientStory...

#MelanomaFocus #PatientStory #SkinCancerAwareness #Immunotherapy #Hope(5/5)

Happening this Friday!

🔗Register: hemehub.org/live-webinars
🔗Case submissions: hemehub.org/case-submiss...

#MultipleMyeloma #Hematology #Oncology #MedicalEducation #PatientCare #Immunotherapy #CellTherapy #NovelTherapies #ClinicalTrials #HemeHub
@mskcancercenter.bsky.social

Personalized Cancer Vaccines Just Hit 5-Year Durability — Here's the Catch Personalized mRNA cancer vaccines show 49% reduction in recurrence at 5 years. Here's how they work, who's behind them, and when patients will actually get acce

49% reduction at five years is the kind of number that actually changes treatment protocols.

Personalized Cancer Vaccines Just Hit 5-Year Durability — Here's the Catch Personalized mRNA cancer vaccines show 49% reduction in recurrence at 5 years. Here's how they work, who's behind them, and when patients will actually get acce

49% reduction sounds huge until you realize we're still waiting on the price tag.

Head & neck cancer care is no longer one-size-fits-all.

From targeted therapy to advanced surgical options, patients today have more choices than ever

www.placidway.com/article/6643/Head-and-Ne...
#headneckcancer #cancercare #immunotherapy

β-hydroxybutyrate enhances the metabolic fitness of CAR T cells in cancer β-hydroxybutyrate (BHB), the ketone body associated with a ketogenic diet, metabolically reprograms and fuels CAR T cells to achieve proliferation, cytokine production, and superior tumor control. The...

A molecule linked to the ketogenic diet may boost cancer #immunotherapy. Researchers found β-hydroxybutyrate (BHB) enhances CAR T cell antitumor activity—pointing to a potential strategy to improve treatment effectiveness. www.cell.com/cell/abstrac...

Excited for the launch of the International #Immunotherapy Society for #FungalDiseases #IISFD 🧫
Join researchers and clinicians in Crete to explore immune-based approaches to fungal infections.
🗓️ Deadlines (Apr 15): abstracts + travel awards
Learn more/apply aegeanconferences.org/conferences/...

Cancer immunotherapy works better earlier in the day - Advanced Science News Patient deaths due to an aggressive form of lung cancer could be halved by simply adjusting the timing of treatment.

Timing matters more than we thought. New research suggests cancer immunotherapy given earlier in the day could significantly improve outcomes and even halve deaths. Small tweak, big impact. #CancerResearch #Immunotherapy #TCSC
www.advancedsciencenews.com/cancer-immun...

How effective is CAR-T therapy in treating melanoma patients? - Answers CAR-T therapy is still in early stages for melanoma and not as effective as it is for blood cancers. Some studies show partial responses (around 35%) and disease control in some patients, but results ...

Melanoma treatment is evolving fast 🚀
Is CAR-T therapy the next big breakthrough?

👉 Get the answer: www.answers.com/biology/How-...

#MelanomaAwareness #Immunotherapy #HealthcareInnovation #MedTech #Science

Flow Forward: Advanced Biomedical Cytometry

For immunologists, oncologists & clinical researchers 🧬
📅 Thursday April 30, 2026 | 10:30am EST
👉 Register: events.bizzabo.com/AdvancedCyto...
#CancerResearch #Immunotherapy #FlowCytometry #ClinicalScience

Scientists inject one tumor and watch cancer vanish across the body A redesigned cancer immunotherapy is showing striking early results after decades of disappointment with similar drugs. Researchers engineered a more powerful CD40 agonist antibody and changed how it’...

A new immunotherapy update is showing remarkable early results: in a phase 1 trial, tumours shrank in 6 of 12 patients and disappeared completely in 2 after direct injection into the tumor site. #CancerTreatment #Immunotherapy #TCSC
Article: www.sciencedaily.com/releases/202...

SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade - Nature mRNA vaccines targeting SARS-CoV-2 also sensitize tumours to immune checkpoint inhibitors.

Encouraging research suggests SARS-CoV-2 mRNA vaccination may be linked with improved survival in some patients receiving immunotherapy for solid tumours, including NSCLC and melanoma. #CancerResearch #Immunotherapy #TCSC
www.nature.com/articles/s41...

Targeting Mettl8-Tcf1 axis promotes CD8⁺ TPEX differentiation and antitumor immunity. New study from Jiaxi Song, Dan Cui, Qizhao Huang, Jia Li, Fengyin Li (University of Science and Technology of China) and colleagues:
rupress.org/jem/article/...

#TumorImmunology #Immunotherapy

Adjuvant immunotherapy for muscle-invasive urothelial carcinoma: Considerations for targeting patients

Bladder Cancer
@journals.sagepub.com

journals.sagepub.com/doi/10.1177/...

#urology #cancer #oncology #biomarker #ctDNA #immunotherapy #openaccess

The prospects of CAR T-cell therapies in changing the therapeutic algorithm of neurologic autoimmunities
@taneuroldisord.bsky.social
@journals.sagepub.com

journals.sagepub.com/doi/10.1177/...

#neurology #inflammation #immunotherapy #medicine #openaccess

Stage 4 breast cancer after chemo can feel like a dead end… 

But immunotherapy could still be an option, especially with the right biomarkers.

www.placidway.com/answer-detail/571353/Is-...

 #fyp  #immunotherapy
#breastcancer

Breakthrough High-Throughput Platform Yields Fast-Acting Covalent Protein Drugs Research from Westlake University reveals a pioneering high-throughput platform for crafting fast-acting covalent protein therapeutics, enhancing their effectiveness.

Breakthrough High-Throughput Platform Yields Fast-Acting Covalent Protein Drugs #China #Hangzhou #Immunotherapy #Westlake_University #Covalent_Drugs

Exposing tumors: Why some cancers are especially hard to treat Some tumors go into

Some cancers are harder to treat because they hide from the immune system. This LJI article explains why “cold” tumors can be so stubborn and how researchers are trying to outsmart them. #CancerResearch #Immunotherapy #TCSC
www.lji.org/news-events/...

Antibiotics and Immunotherapy in Melanoma | Docwire News Antibiotic use during immune checkpoint inhibitor therapy may be associated with improved overall survival among patients with advanced melanoma.

What is the impact of #antibiotic use on #immunotherapy for #melanoma? Check out the results of a retrospective study from Dr Vincent Ma (@uwmadison.bsky.social) at the link!
#Dermatology #Oncology #SkinCancer

www.docwirenews.com/post/impact-...

Breakthrough CAR-T Cell Production Method Could Extend Cancer Remission and Advance HIV Cure Research BRONX, — Scientists from Albert Einstein College of Medicine have unveiled a new technique for producing CAR-T immune cells that may dramatically improve how long these engineered cells remain active in the body, potentially strengthening treatments for blood cancers and bringing researchers closer to long-term HIV control. The findings, reported in the journal Science Advances, …

Breakthrough CAR-T Cell Production Method Could Extend Cancer Remission and Advance HIV Cure Research #CancerResearch #CART #HIVCure #Medicine #Immunotherapy

Amyloid plaques, shown here in pink via a transmission electron micrograph of an Alzheimer's patient's brain. Image credit: Science Source/THOMAS DEERINCK, NCMIR

Reprogrammed #astrocytes clear #Alzheimers #plaques in mice. In PNAS Journal Club: https://ow.ly/MgWU50YCrrr

#AlzheimersDisease #AmyloidPlaque #immunotherapy #AdenoAssociatedVirus

STRIDE Regimen Shows PFS Benefit Alongside TACE and Lenvatinib in Embolization-Eligible Unresectable HCC | OncLive A trend toward improved OS was also observed when the dual immunotherapy regimen was added to TACE and lenvatinib in this patient population.

🧬 The STRIDE regimen (tremelimumab + durvalumab) combined with lenvatinib + TACE significantly improved PFS vs TACE alone in embolization-eligible disease in the phase 3 EMERALD-3 trial 📊
Read more ➡️ www.onclive.com/view/stride-...
#HCC #LiverCancer #Immunotherapy #Oncology

Promotional graphic showing a pink-orange San Diego skyline with text: “Let’s talk about your immunotherapy projects at AACR 2026 • San Diego, California” and the iRepertoire, Inc. logo.

Meet with us in booth #723 at AACR 2026 to learn how our seven-chain immune repertoire sequencing, immunophenotyping, and expert data analysis services can advance your immuno-oncology program.

Explore our services: irepertoire.com/immuno-oncol...

#AACR2026 #Immunotherapy

22-23 PHARMA - Fast and the curious This month: the NHS as a dystopian game of Tetris, the GLP-1 explosion and its impact on future meds, plus deep dives into AI in pharma, reproductive health, and Trump’s healthcare influence. Also, co...

#mRNAvaccines #GLP1 #obesity #CARTcelltherapies #oncology #PCSK9inhibitors #HepatitisC #Immunotherapy #checkpointinhibitors #RSVvaccines #Genetherapies #rarediseases #antivirals #Biosimilars #expandedaccess #biologics #HIV #Migraine #CGRPinhibitors #antifungals #precisionmedicine
zurl.co/3UDz7

Cai and Tang report a 26-year-old male with aggressive T-LGLL and a near tetraploid karyotype. After failing #chemotherapy, he achieved complete remission with Tislelizumab and Pentostatin. No relapse at 6 months suggests a new role for #immunotherapy in aggressive T-LGLL.
doi.org/10.59717/j.x...

Stay in the know with #SITC! Explore our upcoming events, webinars, and important dates by looking at our calendar. Learn More: https://sitcancer.org/get-involved/events/calendar #Immunotherapy

Researchers identified that CCR7 exhibits dual roles in HCC, promoting tumor progression yet enhancing immune response in stromal contexts, offering a #Biomarker for precision therapy and improved #Immunotherapy outcomes. @fudan-university.bsky.social

#STTT #OpenAccess: doi.org/10.1038/s413...

New research shows that adding CD28 signalling motifs to the CD3ζ chain boosts IL‑2 production and expansion of TCR‑engineered T cells, without reducing cytotoxicity. A promising step toward stronger TCR therapies for solid tumours.

Read here: vist.ly/4wxea

#Immunotherapy #TCells

Hanina et al. (2026) report on CAR T cells, engineered for enhanced sensitivity to CD70. The findings open new doors for solid tumor therapy by targeting even tumors with minimal CD70.
Check out the video!
#CancerResearch #Immunotherapy #CARTcells
youtu.be/Kit35JwsocQ